《大行報告》大摩:滔搏(06110.HK)年度純利遠勝預期 評級「增持」
摩根士丹利發表報告指,滔搏(06110.HK)公布截至今年2月底止年度純利遠勝預期,非國際財務報告準則指標經調整純利27.7億人民幣按年升16%,高於該行及市場原先預期。
該行指,滔搏全財年銷售按年升7%,意味下半財年收入按年升21%,大致符該行預期;毛利率按年收縮1.3個百分點至40.8%,符該行預期;受惠成本控制改善及經營槓桿,經調整純利按年升16%,則勝該行及市場預期的低至中雙位數升幅。
大摩料市場對滔搏情緒將改善,核心推動力在未來業績會議管理層對銷售復甦及目標更新的取態。予「增持」評級,目標價15.3元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.